dantrolene has been researched along with Multiple Sclerosis in 26 studies
Dantrolene: Skeletal muscle relaxant that acts by interfering with excitation-contraction coupling in the muscle fiber. It is used in spasticity and other neuromuscular abnormalities. Although the mechanism of action is probably not central, dantrolene is usually grouped with the central muscle relaxants.
dantrolene : The hydrazone resulting from the formal condensation of 5-(4-nitrophenyl)furfural with 1-aminohydantoin. A ryanodine receptor antagonist used for the relief of chronic severe spasticity and malignant hyperthermia.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of dantrolene sodium and diazepam were compared in a double crossover study of 42 patients with spasticity due to stable multiple sclerosis." | 5.04 | Comparison of dantrolene sodium and diazepam in the treatment of spasticity. ( Lee, RH; Schmidt, RT; Spehlmann, R, 1976) |
| "The mode of action of dantrolene sodium was studied in 11 multiple sclerosis patients with spastic paresis of the legs by measurements of changes in electromyographic and mechanomyographic proprioceptive reflex responses and in voluntary power." | 3.66 | Mode of action of dantrolene sodium in spasticity. ( Mai, J; Pedersen, E, 1979) |
| "Treatment of spasticity poses a major challenge given the complex clinical presentation and variable efficacy and safety profiles of available drugs." | 2.53 | Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. ( Comi, G; Gold, R; Hartung, HP; Montalban, X; Otero-Romero, S; Sastre-Garriga, J; Soelberg Sørensen, P; Thompson, AJ; Vermersch, P, 2016) |
| "The medicinal treatment of spasticity includes use of oral treatments (baclofène and tizanidine), botulinum toxin, intrathecal baclofène and local application of alcohol or phenol." | 2.48 | [Pharmacological treatment of spasticity in multiple sclerosis]. ( Heinzlef, O; Monteil-Roch, I, 2012) |
| "Among the more common symptoms is spasticity." | 2.41 | Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis. ( Schapiro, RT, 2001) |
| "Baclofen is the treatment of choice for spasticity and is usually given in doses of 30 to 80 mg/day, although higher doses may be used." | 2.37 | Multiple sclerosis. Current concepts in management. ( Giesser, B, 1985) |
| "Dicyclomine hydrochloride was the drug of choice for detrusor hyperreflexia, bethanechol chloride for hypotonicity, dantrolene sodium for somatic dyssynergia and phenoxybenzamine hydrochloride for sympathetic dyssynergia." | 1.26 | Dysfunction of the detrusor and urethra in multiple sclerosis: the role of drug therapy. ( Awad, SA; Fenemore, J; Kiruluta, HG; Wilson, JW, 1982) |
| "In 25 patients with spasticity, pharmacokinetics and effects of dantrolene sodium were investigated after prolonged administration." | 1.26 | The effect of dantrolene sodium in relation to blood levels in spastic patients after prolonged administration. ( Agoston, S; Bakker, H; Kok, JJ; Meyler, WJ; Wesseling, H, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (80.77) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (7.69) | 29.6817 |
| 2010's | 3 (11.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sturgill, EL | 1 |
| Wittwer, RL | 1 |
| Otero-Romero, S | 1 |
| Sastre-Garriga, J | 1 |
| Comi, G | 1 |
| Hartung, HP | 1 |
| Soelberg Sørensen, P | 1 |
| Thompson, AJ | 1 |
| Vermersch, P | 1 |
| Gold, R | 1 |
| Montalban, X | 1 |
| Kasatkin, DS | 1 |
| Heinzlef, O | 1 |
| Monteil-Roch, I | 1 |
| Awad, SA | 1 |
| Wilson, JW | 1 |
| Fenemore, J | 1 |
| Kiruluta, HG | 1 |
| McLeod, JG | 1 |
| Dimitrijevic, MR | 1 |
| Sherwood, AM | 1 |
| Meyler, WJ | 1 |
| Bakker, H | 1 |
| Kok, JJ | 1 |
| Agoston, S | 1 |
| Wesseling, H | 1 |
| Chantraine, A | 1 |
| van Ouwenaller, C | 1 |
| Cornette, M | 1 |
| Gillard, C | 1 |
| Borlee-Hermans, G | 1 |
| Schapiro, RT | 1 |
| Mai, J | 1 |
| Pedersen, E | 1 |
| Pinder, RM | 1 |
| Brogden, RN | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Schmidt, RT | 2 |
| Lee, RH | 2 |
| Spehlmann, R | 2 |
| Horne, ML | 1 |
| Tolosa, ES | 1 |
| Soll, RW | 1 |
| Loewenson, RB | 1 |
| Giesser, B | 1 |
| Basmajian, JV | 2 |
| Ladd, H | 1 |
| Oist, C | 1 |
| Jonsson, B | 1 |
| Ladd, HW | 1 |
| Gingras, G | 1 |
| Boucher, J | 1 |
| Kazdan, N | 1 |
| Keenan, R | 1 |
| Chyatte, SB | 1 |
| Monster, AW | 2 |
| Glass, A | 1 |
| Hannah, A | 1 |
| Herman, R | 1 |
| Meeks, S | 1 |
| McHenry, J | 1 |
| Gelenberg, AJ | 1 |
| Poskanzer, DC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of EXOPULSE Mollii Suit on Spasticity and Muscular Oxygenation in Patients With Multiple Sclerosis.[NCT05912595] | 36 participants (Anticipated) | Interventional | 2023-05-18 | Recruiting | |||
| The Effects of EXOPULSE Mollii Suit on Motor Functions in Patients With Multiple Sclerosis (EXOSEP 2)[NCT05857280] | 36 participants (Anticipated) | Interventional | 2023-03-21 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for dantrolene and Multiple Sclerosis
| Article | Year |
|---|---|
Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.
Topics: Amines; Analgesics; Baclofen; Cannabidiol; Clonidine; Cyclohexanecarboxylic Acids; Dantrolene; Diaze | 2016 |
[Pharmacological treatment of spasticity in multiple sclerosis].
Topics: Algorithms; Amines; Baclofen; Botulinum Toxins, Type A; Clonidine; Cyclohexanecarboxylic Acids; Dant | 2012 |
Spasticity: medical and surgical treatment.
Topics: Ambulatory Care; Ataxia; Baclofen; Dantrolene; Diazepam; Electric Stimulation; Electrodes; Electroen | 1980 |
Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis.
Topics: Acetates; Amines; Autoimmune Diseases; Baclofen; Benzodiazepines; Botulinum Toxins, Type A; Cannabin | 2001 |
Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity.
Topics: Adult; Animals; Cats; Cerebral Palsy; Chemical and Drug Induced Liver Injury; Child; Clinical Trials | 1977 |
Multiple sclerosis. Current concepts in management.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Baclofen; Dantrolene; Fatigue; Gastrointestina | 1985 |
9 trials available for dantrolene and Multiple Sclerosis
| Article | Year |
|---|---|
Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity.
Topics: Adult; Animals; Cats; Cerebral Palsy; Chemical and Drug Induced Liver Injury; Child; Clinical Trials | 1977 |
Comparison of dantrolene sodium and diazepam in the treatment of spasticity.
Topics: Clinical Trials as Topic; Dantrolene; Diazepam; Humans; Hydantoins; Multiple Sclerosis; Muscle Spast | 1976 |
Letter: Treatment of spasticity in multiple sclerosis with dantrolene.
Topics: Clinical Trials as Topic; Dantrolene; Humans; Hydantoins; Multiple Sclerosis; Placebos; Sodium; Spas | 1975 |
[Attenuating effect of a new pharmacological agent (Dantrolene sodium) on spasticity].
Topics: Adolescent; Adult; Child; Clinical Trials as Topic; Dantrolene; Evaluation Studies as Topic; Humans; | 1973 |
Dantrolene sodium: long-term effects in severe spasticity.
Topics: Activities of Daily Living; Adolescent; Adult; Alkaline Phosphatase; Aspartate Aminotransferases; Ce | 1973 |
Spasticity and the effect of dantrolene sodium.
Topics: Adult; Ankle Joint; Cerebrovascular Disorders; Clinical Trials as Topic; Dantrolene; Dose-Response R | 1974 |
A comparison of dantrolene sodium and diazepam in the treatment of spasticity.
Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Clinical Trials as Topic; Dantrolene; Diazepam; | 1974 |
Cooperative study for assessing the effects of a pharmacological agent on spasticity.
Topics: Adult; Aged; Analog-Digital Conversion; Cerebrovascular Disorders; Computers, Analog; Dantrolene; El | 1973 |
The effect of dantrolene sodium on spasticity in multiple sclerosis.
Topics: Adult; Aged; Dantrolene; Evaluation Studies as Topic; Female; Humans; Hydantoins; Male; Middle Aged; | 1973 |
12 other studies available for dantrolene and Multiple Sclerosis
| Article | Year |
|---|---|
Novel Treatment Using Intravenous Dantrolene Sodium for Postoperative Exacerbated Spasticity in Multiple Sclerosis: A Case Report.
Topics: Administration, Intravenous; Dantrolene; Female; Humans; Middle Aged; Motor Neurons; Multiple Sclero | 2018 |
[Pathogenetic therapy of spasticity].
Topics: Adult; Aged; Animals; Cerebral Palsy; Child; Controlled Clinical Trials as Topic; Dantrolene; Diseas | 2008 |
Dysfunction of the detrusor and urethra in multiple sclerosis: the role of drug therapy.
Topics: Adult; Bethanechol; Bethanechol Compounds; Dantrolene; Dicyclomine; Drug Evaluation; Female; Humans; | 1982 |
When drugs can help in multiple sclerosis.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Baclofen; Dantrolene; Diazepam; Humans; Immuno | 1980 |
The effect of dantrolene sodium in relation to blood levels in spastic patients after prolonged administration.
Topics: Adult; Aged; Brain Concussion; Dantrolene; Dose-Response Relationship, Drug; Female; Humans; Male; M | 1981 |
[Treatment of spasticity in neurological disease by dantrolen-sodium (author's transl)].
Topics: Adolescent; Adult; Aged; Dantrolene; Female; Hemiplegia; Humans; Male; Middle Aged; Multiple Scleros | 1980 |
[Fatal toxic hepatitis associated with administration of dantrolene (author's transl)].
Topics: Chemical and Drug Induced Liver Injury; Cholestasis; Dantrolene; Diabetes Complications; Female; Hum | 1980 |
Mode of action of dantrolene sodium in spasticity.
Topics: Dantrolene; Drug Evaluation; Electromyography; Humans; Injections, Intravenous; Motor Neurons; Multi | 1979 |
Mode of action of dantrolene sodium in spasticity.
Topics: Dantrolene; Drug Evaluation; Electromyography; Humans; Injections, Intravenous; Motor Neurons; Multi | 1979 |
Mode of action of dantrolene sodium in spasticity.
Topics: Dantrolene; Drug Evaluation; Electromyography; Humans; Injections, Intravenous; Motor Neurons; Multi | 1979 |
Mode of action of dantrolene sodium in spasticity.
Topics: Dantrolene; Drug Evaluation; Electromyography; Humans; Injections, Intravenous; Motor Neurons; Multi | 1979 |
Letter: Treatment of spasticity in multiple sclerosis with dantrolene.
Topics: Dantrolene; Humans; Hydantoins; Multiple Sclerosis; Spasm | 1976 |
Treatment of spasticity in multiple sclerosis: comparison of dantrolene sodium and diazepam.
Topics: Dantrolene; Diazepam; Humans; Hydantoins; Multiple Sclerosis; Spasm | 1975 |
Muscle relaxants in multiple sclerosis.
Topics: Baclofen; Dantrolene; Humans; Multiple Sclerosis; Muscle Spasticity | 1987 |
The effect of Dantrium on spasticity in multiple sclerosis.
Topics: Administration, Oral; Adult; Dantrolene; Depression, Chemical; Electromyography; Female; Humans; Hyd | 1974 |